First day of the meeting focused on the rapidly evolving field of cell and gene therapy in neonatal population. The current landscape of gene therapy clinical trials in neonates was discussed, followed by perspectives from stakeholders including industry, academic, regulator, and parent partners of INC. Subsequent discussion focused on the diagnostic platforms for whole genome sequencing, ethical considerations related to diagnosis of genetic conditions and participation in gene therapy trials.

Second day of the meeting focused on the utility of real-world data to generate real-world evidence as it pertains to neonatal research, and how C-Path’s core competencies of data science and analysis applied to real-world data promises to accelerate our understanding of some of the most challenging conditions in the neonatal population.

Access the detailed agenda now. Please reach out to incinfo@c-path.org with any questions.